P1, N=12, Recruiting, University of Michigan Rogel Cancer Center | Not yet recruiting --> Recruiting

When combined with standard agents such as daratumumab, pomalidomide, or cereblon E3 ligase modulatory drugs, forimtamig has shown improved tumor clearance and reduced relapse rates. Currently undergoing phase 1 trials, forimtamig is being evaluated both as monotherapy and in combination regimens. Its high potency, favorable safety, and durable immune engagement make it a promising candidate in the evolving treatment landscape of multiple myeloma.

P3, N=644, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting

P3, N=460, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting

The threshold concentration above which dose escalation is ineffective remains unclear. ClinicalTrials.gov identifier: NCT02896985.

She was treated with a methylprednisolone taper, budesonide and infliximab, resulting in resolution of symptoms. In this case, colitis was successfully managed with corticosteroids and infliximab, allowing for safe re-challenge at a reduced dose. This case highlights the importance of recognizing and managing rare toxicities associated with antibody-drug conjugates to optimize their safe use in ovarian cancer treatment.

P4, N=60, Recruiting, Emory University | N=20 --> 60

In contrast, elevations in general inflammatory markers (white blood cell count, eosinophils, and C-reactive protein) or in lactate dehydrogenase, an indicator of atopic dermatitis, were observed in only a minority of events. These findings suggest that TARC may be a useful biomarker for identifying lenalidomide-induced rash and may aid in optimizing clinical management while maintaining treatment continuity.

This bibliometric analysis highlights the rapidly evolving field of lenalidomide resistance in MM. Future efforts should focus on developing next-generation agents against resistance, designing rational combination therapies targeting key pathways like signal transducer and activator of transcription 3 (STAT3)/ nuclear factor kappa-B (NF-κB), and establishing evidence-based treatment consensus to improve outcomes.

P=N/A, N=18, Active, not recruiting, Alimentiv Inc. | Trial completion date: Mar 2026 --> Dec 2027

Furthermore, adalimumab therapy reversed the increased frequencies of CD80+ macrophages and Th1/Th17 cells in the spleen and in association with remission of uveitis in the EAU model. Adalimumab modulates macrophage polarization to attenuate T cell-mediated inflammation by targeting different proteins in BU and VKH, providing novel insights for precision immunotherapy in uveitis.

P3, N=400, Recruiting, Duke University | Trial primary completion date: Jun 2026 --> Dec 2026